Clinical Trials for Pancreas Cancer

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (G1–2), SSTR-positive pancreatic NETs that are unresectable/metastatic and have progressed after ≥1 prior systemic therapy (no prior PRRT or fulvestrant) receive 177Lu-DOTATATE plus fulvestrant. Fulvestrant, a selective estrogen receptor degrader with potential radiosensitizing effects, is combined with standard PRRT to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06663072

A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic or unresectable PDAC after progression on a 5‑FU–based regimen (no prior gemcitabine/nab‑paclitaxel for advanced disease) receive emavusertib (CA‑4948), an oral IRAK4/FLT3 inhibitor targeting TLR/IL‑1R–NF‑κB signaling, combined with fixed-dose gemcitabine and nab‑paclitaxel. Prior gemcitabine in the adjuvant setting (>12 months) is allowed; ECOG 0–2 required; controlled HIV/HBV/HCV and treated, stable brain metastases permitted.

ClinicalTrials.gov ID: NCT05685602

A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (dose-escalation monotherapy) or treatment‑naïve, CLDN18.2‑positive gastric/GEJ/esophageal adenocarcinoma (combination cohorts) receive givastomig (TJ033721/ABL111), a CLDN18.2 × 4‑1BB bispecific antibody that conditionally activates 4‑1BB on T cells, either alone or with nivolumab plus chemotherapy. Key requirements include ECOG 0–1, known PD‑L1 CPS, CLDN18.2 positivity for expansion/combination, and no prior CLDN18.2 therapy or prior PD‑1/PD‑L1 therapy in the combination setting.

ClinicalTrials.gov ID: NCT04900818

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) without prior pancreatic radiation receive stereotactic-like adaptive radiation therapy in 5 every-other-day fractions after optional induction chemotherapy. The trial escalates ART dose to biologically aggressive tumor regions while sparing organs-at-risk, with primary focus on grade ≥3 GI toxicity and secondary measures of local control and survival.

ClinicalTrials.gov ID: NCT06984562

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma who have disease control after 4–6 months of first-line chemotherapy (FOLFIRINOX/mFOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel) are randomized to standard post-induction management (continue chemo, standard-dose chemoradiation with 5-FU/capecitabine, or observation) versus dose‑escalated radiation (preferably 5 fractions; or 25 fractions with optional 5-FU/capecitabine), with chemotherapy completion to 6 months as needed. No investigational drugs are used; the trial tests whether higher-dose, precision RT improves survival.

ClinicalTrials.gov ID: NCT06958328

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic PDAC and cancer-associated cachexia (ECOG 0–1) beginning next cycle of first-line nab-paclitaxel/gemcitabine or (m)FOLFIRINOX are randomized to add ponsegromab, a subcutaneous anti–GDF-15 monoclonal antibody aimed at improving appetite/weight and function, versus placebo. Investigational therapy is given Q4W alongside standard chemotherapy; exclusions include reversible anorexia causes, CNS metastases, significant cardiac dysfunction, severe hepatic/renal impairment, and tube or parenteral feeding.

ClinicalTrials.gov ID: NCT06989437

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with measurable metastatic or recurrent pancreatic adenocarcinoma (ECOG 0–1) who have not received prior systemic therapy for metastatic disease (adjuvant/neoadjuvant allowed if completed ≥12 months prior) and have adequate organ function. Treatment is first-line nivolumab (anti–PD-1) plus gemcitabine/nab-paclitaxel with added BMS-986340 (imzokitug), an investigational nonfucosylated anti-CCR8 IgG1 designed to block CCR8 and deplete CCR8+ tumor-infiltrating Tregs via ADCC, given in 28-day cycles until progression/toxicity (up to 2 years).

ClinicalTrials.gov ID: NCT07226856

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 metastatic pancreatic ductal adenocarcinoma who have a documented SWI/SNF chromatin-remodeling gene alteration (e.g., ARID1A/ARID1B, PBRM1, SMARCA4, SMARCB1) and have received exactly one prior systemic line for metastatic disease and are immunotherapy-naïve. Patients receive cemiplimab (anti–PD-1 checkpoint inhibitor) plus gemcitabine chemotherapy until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT06790602

A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed (within 6 weeks), previously untreated metastatic pancreatic adenocarcinoma with measurable disease (RECIST 1.1) and ECOG 0–1 (excluding prior gemcitabine/nab-paclitaxel exposure for PDAC, significant neuropathy, chronic steroid need, active HIV/HBV/HCV, uncontrolled CNS mets, and known BRCA mutations) receive first-line nab-paclitaxel plus gemcitabine. Relacorilant, an investigational selective glucocorticoid receptor antagonist/modulator aimed at reducing cortisol-driven GR signaling and taxane resistance, is given orally 150 mg daily for 3 days around each chemotherapy dose in 28-day cycles until progression or toxicity.

ClinicalTrials.gov ID: NCT07259317

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma that is tissue-confirmed KRAS wild type and BRAF V600E wild type, ECOG 0–2, who have progressed on/intolerant of exactly one prior systemic cytotoxic regimen for advanced disease. Patients are randomized to investigator-chosen second-line chemotherapy (nal-IRI/5-FU/LV, irinotecan/5-FU/LV, or nab-paclitaxel/gemcitabine) with or without panitumumab, an anti-EGFR monoclonal antibody that blocks EGFR signaling.

ClinicalTrials.gov ID: NCT06998940